[68Ga]PSMA-HBED PET for differential diagnosis of suspicious lung lesions in patients with prostate cancer

RATIONALE - In prostate cancer (PC) patients, differentiation between lung metastases and lesions of different origin, e.g. primary lung cancer, is a common clinical question. Herein we investigate the use of (68)Ga-PSMA-HBED-CC for this purpose.

METHODS - 1889 PC patients receiving (68)Ga-PSMA PET/CT or PET/MR scans were evaluated retrospectively for suspicious lung lesions. For up to 5 lesions per patient, location, CT diameter, CT morphology and SUVmax values were determined. Standard for classification was either histopathologic evaluation or, in case of PC metastases, responsivity to anti-hormone therapy. Comparison of the different classes was executed by Student's t test. PSA and PSMA immunohistochemistry were performed if histologic samples were available; (68)Ga-PSMA autoradiography was performed on an exemplary case of PET positive lung cancer.

RESULTS - 89 lesions in 45 patients were identified, of which 76 were classified as PC (39 proven, 37 highly probable), 7 as primary lung cancer and 2 as activated tuberculosis; 4 lesions remained unclear. The mean SUVmax was 4. 4±3. 9 for PC metastases and 5. 6±1. 6 for primary lung cancer (P = 0. 408). Additionally, substantial differences in SUVmax values intra-individually were detected. The two tuberculous lesions showed an SUVmax of 7. 8 and 2. 5, respectively. Using immunohistochemistry, we could demonstrate PSMA expression in the neo-vasculature of several PSMA PET positive lung cancers, as well as in tuberculous lesions from our histologic database.

CONCLUSION - Quantitative (SUV) analysis of (68)Ga-PSMA PET was not able to discriminate reliably between pulmonary metastases and primary lung cancer in PC patients. The reason for the unexpectedly high tracer uptake in non-PC lesions is not completely clear. PSMA expression in neo-vasculature provides a possible explanation for this finding; however, other contributing factors, such as tracer binding to proteins other than PSMA, cannot be excluded at present.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015 Nov 19 [Epub ahead of print]

Thomas Pyka, Gregor Weirich, Ingo Einspieler, Tobias Maurer, Joerg Theisen, Georgios Hatzichristodoulou, Kristina Schwamborn, Markus Schwaiger, Matthias Eiber

Technische Universität München, Germany. , Technische Universität München, Germany. , Technische Universität München, Germany. , Technische Universität München, Germany. , Technische Universität München, Germany. , Technische Universität München, Germany. , Technische Universität München, Germany. , Technische Universität München, Germany. , Technische Universität München, Germany.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe